Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer

Molecular Endocrinology

Volumn 26, Issue 4, 2012, Pages 550-561

  Yang, Lin ^a,b   Ravindranathan, Preethi ^a   Ramanan, Meera ^a   Kapur, Payal ^a   Hammes, Stephen R ^c   Hsieh, Jer Tsong ^a,d   Raj, Ganesh V ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; PEPTIDES AND PROTEINS; PROLINE GLUTAMIC ACID AND LEUCINE RICH COFACTOR PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; COMPLEX FORMATION; GENE; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CO-REPRESSOR PROTEINS; DIHYDROTESTOSTERONE; ESTRADIOL; ESTROGEN RECEPTOR BETA; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; MULTIPROTEIN COMPLEXES; NEOPLASM GRADING; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84859153574     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1101     Document Type: Article

References (46)

1. Knudsen KE, Scher HI 2009 Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15:4792-4798
2. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
3. Chen Y, Sawyers CL, Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448
4. Edwards J, Bartlett JM 2005 The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 95:1320-1326
5. Takahashi Y, Perkins SN, Hursting SD, Wang TT 2007 17β-estradiol differentially regulates androgen-responsive genes through estrogen receptor-β-and extracellular-signal regulated kinase-dependent pathways in LNCaP human prostate cancer cells. Mol Carcinog 46:117-129
6. Risbridger GP, Ellem SJ, McPherson SJ 2007 Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 39:183-188
7. Li LC, Carroll PR, Dahiya R 2005 Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97:103-115
8. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R 2000 Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 60:702-706
9. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM 2001 Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159:79-92
10. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E 2004 Metastases of prostate cancer express estrogen receptor-β. Urology 64:814-820
11. Ito T, Tachibana M, Yamamoto S, Nakashima J, Murai M 2001 Expression of estrogen receptor (ER-α and ER-β) mRNA in human prostate cancer. Eur Urol 40:557-563
12. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL 2001 Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res 61:5331-5335
13. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA 2008 Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100:815-825
14. Signoretti S, Loda M 2001 Estrogen receptor β in prostate cancer: brake pedal or accelerator? Am J Pathol 159:13-16
15. Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A, Sinisi AA 2001 Loss of estrogen receptor β expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 86:2051-2055
16. Pravettoni A, Mornati O, Martini PG, Marino M, Colciago A, Celotti F, Motta M, Negri-Cesi P 2007 Estrogen receptor β (ERβ) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol 263:46-54
17. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP 2010 Estrogen receptor-β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. Proc Natl Acad Sci USA 107:3123-3128
18. Benbrahim-Tallaa L, Liu J, Webber MM, Waalkes MP 2007 Estro-gen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells. Prostate 67:135-145
19. Carruba G 2006 Estrogens and mechanisms of prostate cancer progression. Ann NY Acad Sci 1089:201-217
20. Heemers HV, Regan KM, Schmidt LJ, Anderson SK, Ballman KV, Tindall DJ 2009 Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol 23:572-583
21. Edwards J, Bartlett JM 2005 The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 95: 1327-1335
22. Brooke GN, Parker MG, Bevan CL 2008 Mechanisms of androgen receptor activation in advanced prostate cancer: differential coactivator recruitment and gene expression. Oncogene 27:2941-2950
23. Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N, Tekmal RR, Broaddus RR, Vadlamudi RK 2008 Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 68:4902-4909
24. Chakravarty D, Tekmal RR, Vadlamudi RK 2010 PELP1: a novel therapeutic target for hormonal cancers. IUBMB Life 62:162-169
25. Haas D, White SN, Lutz LB, Rasar M, Hammes SR 2005 The modulator of nongenomic actions of the estrogen receptor (MNAR) regulates transcription-independent androgen receptormediated signaling: evidence that MNAR participates in G proteinregulated meiosis in Xenopus laevis oocytes. Mol Endocrinol 19: 2035-2046
26. Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schüle R, Brann DW, Tekmal RR, Vadlamudi RK 2010 PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-β target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 11:438-444
27. Choi YB, Ko JK, Shin J 2004 The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains. J Biol Chem 279:50930-50941
28. Brann DW, Zhang QG, Wang RM, Mahesh VB, Vadlamudi RK 2008 PELP1-a novel estrogen receptor-interacting protein. Mol Cell Endocrinol 290:2-7
29. Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR, Ellis IO 2010 The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminallike subtype. Breast Cancer Res Treat 120:603-612
30. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK 2011 Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 17:2250-2259
31. Cheskis BJ, Greger J, Cooch N, McNally C, Mclarney S, Lam HS, Rutledge S, Mekonnen B, Hauze D, Nagpal S, Freedman LP 2008 MNARplays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 73:901-905
32. Prins GS 2008 Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 15:649-656
33. Singh PB, Matanhelia SS, Martin FL 2008 A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 44:928-936
34. Prins GS, Korach KS 2008 The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73:233-244
35. Ellem SJ, Risbridger GP 2006 Aromatase and prostate cancer. Minerva Endocrinol 31:1-12
36. Prins GS, Putz O 2008 Molecular signaling pathways that regulate prostate gland development. Differentiation 76:641-659
37. McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP 2001 Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142:2458-2467
38. Fujimoto N, Suzuki T, Honda H, Kitamura S 2004 Estrogen enhancement of androgen-responsive gene expression in hormoneinduced hyperplasia in the ventral prostate of F344 rats. Cancer Sci 95:711-715
39. Härkönen PL, Mäkelä SI 2004 Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 92:297-305
40. Nair S, Vadlamudi RK 2007 Emerging significance of ER-coregulator PELP1/MNAR in cancer. Histol Histopathol 22:91-96
41. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, Kumar R 2001 Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor β. J Biol Chem 276: 38272-38279
42. Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, Schüle R, Kung HJ, Kumar R, Vadlamudi RK 2007 Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol 21:613-624
43. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S, Buluwela L 2009 Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28:2051-2063
44. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 173:534-540
45. Vadlamudi RK, Kumar R 2007 Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 5:e004
46. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K 2001 Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate 48:285-291